Compugen Ltd
Compugen Ltd. is a U.S.-listed, Israel-based biopharmaceutical company focused on computationally discovered cancer immunotherapy programs. The company develops antibody-based drug candidates and also licenses selected programs to larger pharmaceutical partners for further development and commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAI/ML-enabled computational discovery tools used to identify novel targets and pathways.
Internally developed antibody candidates such as COM902 advanced in clinical development.
Programs licensed to pharmaceutical partners for development, regulatory and commercial milestones.
Customers
Compugen’s direct customers are primarily pharmaceutical and biotechnology partners that license programs or fund development through collaboration agreements. Its end-market, however, is oncology patients treated through hospitals and cancer centers once partnered or proprietary therapies reach commercialization. The company also serves research and clinical stakeholders who use its discovery platform and programs for target validation and development decisions.
License programs such as COM902-derived assets to fund development, milestones and future royalties.
Use the discovery platform and antibody assets to access differentiated cancer immunotherapy programs.
Hospitals and cancer centers are the eventual users of approved therapies developed from the pipeline.
Strategy
Compugen’s strategy centers on using its computational discovery platform to generate novel immuno-oncology targets and then advancing a select number of programs internally or with partners. The company also seeks to monetize its science through licensing structures that can deliver upfront payments, milestones and royalties while limiting full commercialization burden.
Internal clinical progress is needed to create future value and strengthen negotiating power with partners.
Milestones and royalties can fund discovery work without requiring full commercialization investment.
A repeatable discovery engine is essential in a target-rich but highly competitive oncology market.
Geography
Compugen’s corporate and research footprint is centered in Israel, with clinical operations also in the United States. Revenue disclosed in the interim report was entirely from U.S. customers, while Europe showed no revenue in the cited period. The geography matters because discovery and development activities are concentrated in Israel, but commercialization and customer invoicing can be tied to partner and end-customer locations.
Risks
Compugen faces the core risks of a clinical-stage biotech company: pipeline failure, long development timelines and dependence on external partners for commercialization of licensed assets. Revenue is concentrated in collaboration and license economics, so delays in partner progression, trial setbacks or lower-than-expected milestones can materially affect future cash generation.
- Clinical development riskImpact: CriticalLikelihood: High
Pipeline candidates can fail in early or late-stage studies, which would reduce or eliminate future program value.
Exposure: COM902 and partnered immuno-oncology assets
- Partner concentration and execution riskImpact: HighLikelihood: Medium
A large share of economics depends on AstraZeneca and other partners progressing programs successfully.
Exposure: Licensed antibody programs and milestone streams
- Regulatory approval riskImpact: HighLikelihood: Medium
Even promising drug candidates require extensive safety and efficacy evidence before approval.
Exposure: Immuno-oncology pipeline
- Funding and burn riskImpact: HighLikelihood: Medium
Clinical-stage biotech companies typically rely on cash, licensing proceeds and capital markets to fund operations.
Exposure: R&D and clinical operations
Accounting
Judgemental itemsCollaboration agreements may include upfront, development, regulatory and commercial payments recognized at different times.
Impact: Affects reported revenue timing and deferred revenue balances
The company reported deferred revenue and revenue not yet recognized from ongoing obligations.
Impact: Affects visibility into future revenue recognition
Equity-based awards are included in segment expense and can materially affect operating results.
Impact: Affects operating expense and non-cash cost structure
Similar listed companies
Publicly listed companies with a comparable business focus.
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Biogen Inc
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
Purple Biotech Ltd
PPBT · Pharmaceutical Preparations
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Adagene Inc.
ADAG · Pharmaceutical Preparations
UroGen Pharma Ltd.
URGN · Pharmaceutical Preparations
Last updated: 28/09/2026